GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Piotroski F-Score

GlobeImmune (GlobeImmune) Piotroski F-Score : 0 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GlobeImmune has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for GlobeImmune's Piotroski F-Score or its related term are showing as below:


GlobeImmune Piotroski F-Score Historical Data

The historical data trend for GlobeImmune's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune Piotroski F-Score Chart

GlobeImmune Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Piotroski F-Score
Get a 7-Day Free Trial - - - - 2.00

GlobeImmune Quarterly Data
Dec10 Mar11 Jun11 Dec11 Mar12 Jun12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar16) TTM:Last Year (Mar15) TTM:
Net Income was -1.305 + 0.894 + -0.795 + -0.862 = $-2.07 Mil.
Cash Flow from Operations was -1.981 + -1.308 + -1.408 + -1.207 = $-5.90 Mil.
Revenue was 1.277 + 2.945 + 1.048 + 0.943 = $6.21 Mil.
Gross Profit was 1.277 + 2.945 + 1.048 + 0.943 = $6.21 Mil.
Average Total Assets from the begining of this year (Mar15)
to the end of this year (Mar16) was
(15.444 + 13.535 + 13.212 + 11.506 + 9.771) / 5 = $12.6936 Mil.
Total Assets at the begining of this year (Mar15) was $15.44 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $9.45 Mil.
Total Current Liabilities was $4.15 Mil.
Net Income was -5.714 + -6.361 + -1.741 + -1.561 = $-15.38 Mil.

Revenue was 1.731 + 1.306 + 1.511 + 1.188 = $5.74 Mil.
Gross Profit was 1.731 + 1.306 + 1.511 + 1.188 = $5.74 Mil.
Average Total Assets from the begining of last year (Mar14)
to the end of last year (Mar15) was
(12.087 + 10.213 + 20.664 + 18.368 + 15.444) / 5 = $15.3552 Mil.
Total Assets at the begining of last year (Mar14) was $12.09 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $14.94 Mil.
Total Current Liabilities was $4.57 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GlobeImmune's current Net Income (TTM) was -2.07. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GlobeImmune's current Cash Flow from Operations (TTM) was -5.90. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar15)
=-2.068/15.444
=-0.13390313

ROA (Last Year)=Net Income/Total Assets (Mar14)
=-15.377/12.087
=-1.27219327

GlobeImmune's return on assets of this year was -0.13390313. GlobeImmune's return on assets of last year was -1.27219327. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GlobeImmune's current Net Income (TTM) was -2.07. GlobeImmune's current Cash Flow from Operations (TTM) was -5.90. ==> -5.90 <= -2.07 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar15 to Mar16
=0/12.6936
=0

Gearing (Last Year: Mar15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar14 to Mar15
=0/15.3552
=0

GlobeImmune's gearing of this year was 0. GlobeImmune's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar16)=Total Current Assets/Total Current Liabilities
=9.45/4.145
=2.27985525

Current Ratio (Last Year: Mar15)=Total Current Assets/Total Current Liabilities
=14.943/4.568
=3.27123468

GlobeImmune's current ratio of this year was 2.27985525. GlobeImmune's current ratio of last year was 3.27123468. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GlobeImmune's number of shares in issue this year was 5.752. GlobeImmune's number of shares in issue last year was 5.752. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6.213/6.213
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5.736/5.736
=1

GlobeImmune's gross margin of this year was 1. GlobeImmune's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar15)
=6.213/15.444
=0.40229215

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar14)
=5.736/12.087
=0.47455944

GlobeImmune's asset turnover of this year was 0.40229215. GlobeImmune's asset turnover of last year was 0.47455944. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GlobeImmune has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

GlobeImmune  (OTCPK:GBIM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


GlobeImmune Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines